Charney Laurence N's Form 4 filing
TG Therapeutics, Inc.TGTX · filed Nov 12, 2024
- Accession no.
- 0001437749-24-034595
- Filed
- Nov 12, 2024
- Trade date
- Nov 11-12, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $755.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Charney Laurence NCIK 0001407451 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2024 | Common Stock | SSaleDisposed | −25,000 | $30.20F1 | −$755,000 | 212,479 | Direct | |
| Nov 12, 2024 | Common Stock | GGiftDisposed | −5,000 | $0.00 | $0 | 207,479 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects the weighted average sale price. The range of prices for the shares sold was $30.17 to $30.29. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.